synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
retinoblastoma protein (pRb) binding motif; cyclin box domain for cyclin-dependent kinase (CDK) binding and CDK inhibitor binding; LxxLL binding motif for co-activator recruitment; PEST sequence that may mark the protein for degradation; threonine residue (threonine 286) that controls nuclear export and protein stability.
== Design considerations == Fabricating artificial skin has the difficulty of mimicking living tissue with similar biological and mechanical performance. As outlined by Integra founders Yannas and Burke, there are three key factors to consider in the creation of artificial skin: material, bio/physiochemical properties, and mechanical properties.
Itraconazole: Increased plasma level of buspirone Rifampicin: Decreased plasma levels of buspirone Nefazodone: Increased plasma levels of buspirone Haloperidol: Increased plasma levels of buspirone Carbamazepine: Decreased plasma levels of buspirone Grapefruit: Significantly increases the plasma levels of buspirone. See grapefruit–drug interactions. Fluvoxamine: Moderately increased plasma levels of buspirone. Elevated blood pressure has been reported when buspirone has been administered to patients taking monoamine oxidase inhibitors (MAOIs). Buspirone has been found to markedly reduce the hallucinogenic effects of the serotonergic psychedelic psilocybin in humans. This parallels findings in which serotonin 5-HT1A receptor agonists like 8-OH-DPAT attenuate the head-twitch response, a behavioral proxy of psychedelic effects, induced by serotonergic psychedelics in rodents. Paradoxically, however, buspirone enhances the head-twitch response, a behavioral proxy of psychedelic effects, induced by 5-hydroxytryptophan (5-HTP) plus pargyline in rodents.
In mid-November 2025, Hangman's Chair announced on their social media that the band was taking a "hiatus for an indefinite period" and that their online merchandise store would close on 31 December. They added that "the shop will reopen as soon as the band becomes active again". In December 2025, Hangman's Chair were included on Rock Sound France's "Top 20 French rock bands" list, which encompassed musical groups from the 1970s–1980s era to the present day.
Sources: en.wikipedia.org
=== Category:EC 1.13 (act on single donors with incorporation of molecular oxygen) === Category:EC 1.13.11 (With incorporation of two atoms of oxygen) 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) Category:EC 1.13.12 (With incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)) Renilla-luciferin 2-monooxygenase EC 1.13.12.5 Cypridina-luciferin 2-monooxygenase EC 1.13.12.6 Firefly luciferase EC 1.13.12.7 Watasenia-luciferin 2-monooxygenase EC 1.13.12.8 Oplophorus-luciferin 2-monooxygenase EC 1.13.12.13
=== Vietnam war activism === During the 1960s, President Lyndon B. Johnson's policy of increasing America's involvement in the Vietnam War caused an anti-war movement that the Paulings joined with enthusiasm. Pauling denounced the war as unnecessary and unconstitutional. He made speeches, signed protest letters and communicated personally with the North Vietnamese leader, Ho Chi Minh, and gave the lengthy written response to President Johnson. His efforts were ignored by the American government.
==== New Zealand ==== The first New Zealand store opened in Manukau, Auckland in 2001; three others also opened in Auckland that year. By 2017, it had 12 Auckland stores and two other cities. By 2022, it had 15 Auckland stores and three other cities.
== Cultivation == Cut flower cultivation is intensive, usually on the basis of greenhouse monocultures, and requires large amounts of highly toxic pesticides, residues of which can often still be found in flower shops on imported flowers. As with the production of fruit and vegetables, the industry depends on significant amounts of water, which may be collected and stored by the farm owners. The Patel Dam failure in May 2018, associated with a large Kenyan rose farm, killed dozens of people. These facts have spurred the development of movements like "Slow Flowers", which propagates sustainable floriculture in the consumer country (US, Canada) itself.
The milli mass unit or (mmu) is used as a unit of mass by some scientific authors even though this unit is not defined by the IUPAP red book nor by the IUPAC green book. It is a short form of the more formally correct "milli unified atomic mass unit" (mu) and equivalent to 1/1000 of the unified atomic mass unit (u). A more modern name is the millidalton (mDa) since the "unified atomic mass unit" has is being superseded by the dalton (1 Da = 1 u). Since 1961 the unified atomic mass unit "u" has been defined as 1⁄12 the mass of 12C. Before that the atomic mass unit "amu" was defined as 1⁄16 the mass of 16O (physics) and as 1⁄16 the mass of O (chemistry). Thus the publication date in literature ought to be heeded when reading about the milli mass unit as its name does not reveal whether it refers to the old amu or the newer u. The mass excess is usually indicated in mu or mmu. In mass spectrometry the mass accuracy of a mass analyzer is often indicated in mu, even though a more correct unit would be mTh (millithomson) since mass spectrometers measure the mass-to-charge ratio, not the mass. The relative mass accuracy is often indicated in ppm, even though this is no longer supported by the IUPAC green book which suggests using units like μTh/Th instead of ppm.
Sources: en.wikipedia.org
Williams contributed to understanding of the distribution of the chemical elements in living organisms and in collaborationwith João J. R. Fraústo da Silva he wrote three books in this area, as well as a book with Rosalind Rickaby on geological aspects of life. Williams retired in 1991 and devoted much of his retirement to the writing of the books mentioned.
Before Roemer's time in office, Louisiana had no limits on individual campaign contributions, which allowed donors to cut massive checks to campaigns without reporting the contributions. Roemer placed Kennedy in charge of his quest to toughen campaign finance laws, including placing a $5,000 cap on individual contributions to statewide candidates. In addition to ushering in the passage of campaign finance and product liability reforms for Roemer's administration, Kennedy led the effort to consolidate Louisiana's four boards of higher education into one. He said the policy would be "fundamental" to improving Louisiana universities' "quality and desegregation". That effort eventually came one vote short of passage. Roemer lost his reelection bid in 1991, but ran again in 1995 with Kennedy as his campaign manager. Roemer later endorsed Kennedy's bids for Senate. Kennedy remained close to Roemer until his death in 2021 and credited the former governor for getting him involved in public service.
Molomo described the Selous Scouts in 2009 as "a terrorist unit within the Rhodesian security forces". Piers Brendon wrote in 2010 that "the Selous Scouts committed the worst atrocities" of any Rhodesian unit. Ian Martinez has written that the Selous Scout's killings of prisoners and use of chemical and biological weapons were war crimes.
Nautiluses are the only extant cephalopods with a true external shell. However, all molluscan shells are formed from the ectoderm (outer layer of the embryo); in cuttlefish (Sepia spp.), for example, an invagination of the ectoderm forms during the embryonic period, resulting in a shell (cuttlebone) that is internal in the adult. The same is true of the chitinous gladius of squid and octopuses. Cirrate octopods have arch-shaped cartilaginous fin supports, which are sometimes referred to as a "shell vestige" or "gladius". The Incirrina have either a pair of rod-shaped stylets or no vestige of an internal shell, and some squid also lack a gladius. The shelled coleoids do not form a clade or even a paraphyletic group. The Spirula shell begins as an organic structure, and is then very rapidly mineralized. Shells that are "lost" may be lost by resorption of the calcium carbonate component. Females of the octopus genus Argonauta secrete a specialized paper-thin egg case in which they reside, and this is popularly regarded as a "shell", although it is not attached to the body of the animal and has a separate evolutionary origin. The largest group of shelled cephalopods, the ammonites, are extinct, but their shells are very common as fossils. Ammonites thrived during the Paleozoic and Mesozoic eras. Their distinctive, spiral-shaped shells are found in sedimentary rocks worldwide and subsequently in many human creations.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.